All In Biotech

NDA 007513 · Hospira

Levophed

Norepinephrine Bitartrate · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Oct 21, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1950

Jul 13, 1950

Approved uses

1

Original approval plus efficacy supplements

Registered trials

13

2 Phase 3, 2 recruiting

FAERS reports

4,217

4,010 serious, 1,717 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 12, 2025.

LEVOPHED is indicated to raise blood pressure in adult patients with severe, acute hypotension. LEVOPHED is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states. ( 1 )

Mechanism: Norepinephrine is a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 13, 1950 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • LEVOPHED · NOREPINEPHRINE BITARTRATE EQ 1MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Norepinephrine Bitartrate" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • renal failure520
  • drug ineffective508
  • pain454
  • hypotension437
  • condition aggravated400
  • stress393
  • sepsis386
  • injury364
  • death363
  • off label use352
  • anxiety344
  • unevaluable event333

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200468
200537
200677
200793
200875
2009102
201094
2011508
2012154
201337
201452
201551
201687
201777
2018105
2019135
2020241
2021239
2022223
2023293
2024257
2025721
2026490

Recalls

2 FDA enforcement reports for this application.

  • Aug 22, 2017 · Class II · Terminated

    Lack of sterility assurance: resulting from use of a damaged sterilizing filter for nitrogen used in the manufacturing process.

  • May 18, 2017 · Class II · Terminated

    GMP Deviation; A foreign stopper was observed during packaging of a lot of product.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.